Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

De Novo Multiple Myeloma
Anitocabtagene Autoleucel

Interventions

DRUG: Daratumumab
DRUG: Isatuximab
DRUG: Bortezomib
DRUG: Lenalidomide
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Anitocabtagene Autoleucel

Sponsor

PETHEMA Foundation